These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 17925885)

  • 1. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
    Zareba KM
    Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in paroxysmal nocturnal haemoglobinuria.
    Charneski L; Patel PN
    Drugs; 2008; 68(10):1341-6. PubMed ID: 18578555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
    Dmytrijuk A; Robie-Suh K; Cohen MH; Rieves D; Weiss K; Pazdur R
    Oncologist; 2008 Sep; 13(9):993-1000. PubMed ID: 18784156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab for paroxysmal nocturnal haemoglobinuria.
    Parker C
    Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
    Hill A; Richards SJ; Rother RP; Hillmen P
    Haematologica; 2007 Mar; 92(3):e31-3. PubMed ID: 17405753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
    Nishimura JI
    Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
    Röth A; Dührsen U
    Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
    Szer J; Hill A; Weitz IC
    Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
    Sicre de Fontbrune F; Peffault de Latour R
    Semin Hematol; 2018 Jul; 55(3):124-129. PubMed ID: 30032748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful management of orthopedic operations requiring general anesthesia in a PNH patient after introduction of eculizumab].
    Tsutsui M; Gotoh A; Yasuda H; Ono E; Tanaka M; Komatsu N
    Rinsho Ketsueki; 2015 Apr; 56(4):423-7. PubMed ID: 25971274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Paroxysmal nocturnal hemoglobinuria: from physiopathology to treatment].
    Arruda MM; Rodrigues CA; Yamamoto M; Figueiredo MS
    Rev Assoc Med Bras (1992); 2010; 56(2):214-21. PubMed ID: 20498998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Höchsmann B
    Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.